P04637

※ Protein Information

Tag	Content
UniProt Accession	P53_HUMAN; P04637;
Entrez ID	7157
GenBank Protein ID	NM_000546.5; NM_001126112.2; NM_001126113.2; NM_001126114.2; NM_001126115.1; NM_001126116.1; NM_001126117.1; NM_001126118.1; NM_001276695.1; NM_001276696.1; NM_001276697.1; NM_001276698.1; NM_001276699.1; NM_001276760.1; NM_001276761.1;
GenBank Nucleotide ID	NP_000537.3; NP_001119584.1; NP_001119585.1; NP_001119586.1; NP_001119587.1; NP_001119588.1; NP_001119589.1; NP_001119590.1; NP_001263624.1; NP_001263625.1; NP_001263626.1; NP_001263627.1; NP_001263628.1; NP_001263689.1; NP_001263690.1;
Protein Name	Cellular tumor antigen p53 (Antigen NY-CO-13) (Phosphoprotein p53) (Tumor suppressor p53)
Gene Name	TP53; P53
Organism	Homo sapiens
NCBI Taxa ID	9606
Functional Description	Acts as a tumor suppressor in many tumor types; induces growth arrest or apoptosis depending on the physiological circumstances and cell type. Involved in cell cycle regulation as a trans-activator that acts to negatively regulate cell division by controlling a set of genes required for this process. One of the activated genes is an inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be mediated either by stimulation of BAX and FAS antigen expression, or by repression of Bcl-2 expression. In cooperation with mitochondrial PPIF i(view all) Functional Description Acts as a tumor suppressor in many tumor types; induces growth arrest or apoptosis depending on the physiological circumstances and cell type. Involved in cell cycle regulation as a trans-activator that acts to negatively regulate cell division by controlling a set of genes required for this process. One of the activated genes is an inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be mediated either by stimulation of BAX and FAS antigen expression, or by repression of Bcl-2 expression. In cooperation with mitochondrial PPIF is involved in activating oxidative stress-induced necrosis; the function is largely independent of transcription. Induces the transcription of long intergenic non-coding RNA p21 (lincRNA-p21) and lincRNA-Mkln1. LincRNA-p21 participates in TP53-dependent transcriptional repression leading to apoptosis and seem to have to effect on cell-cycle regulation. Implicated in Notch signaling cross-over. Prevents CDK7 kinase activity when associated to CAK complex in response to DNA damage, thus stopping cell cycle progression. Isoform 2 enhances the transactivation activity of isoform 1 from some but not all TP53-inducible promoters. Isoform 4 suppresses transactivation activity and impairs growth suppression mediated by isoform 1. Isoform 7 inhibits isoform 1-mediated apoptosis. Regulates the circadian clock by repressing CLOCK-ARNTL/BMAL1-mediated transcriptional activation of PER2 (PubMed:24051492).
Sequence (Fasta)	MEEPQSDPSV EPPLSQETFS DLWKLLPENN VLSPLPSQAM DDLMLSPDDI EQWFTEDPGP 60 DEAPRMPEAA PPVAPAPAAP TPAAPAPAPS WPLSSSVPSQ KTYQGSYGFR LGFLHSGTAK 120 SVTCTYSPAL NKMFCQLAKT CPVQLWVDST PPPGTRVRAM AIYKQSQHMT EVVRRCPHHE 180 RCSDSDGLAP PQHLIRVEGN LRVEYLDDRN TFRHSVVVPY EPPEVGSDCT TIHYNYMCNS 240 SCMGGMNRRP ILTIITLEDS SGNLLGRNSF EVRVCACPGR DRRTEEENLR KKGEPHHELP 300 PGSTKRALPN NTSSSPQPKK KPLDGEYFTL QIRGRERFEM FRELNEALEL KDAQAGKEPG 360 GSRAHSSHLK SKKGQSTSRH KKLMFKTEGP DSD 394 Fasta Sequence >P04637\|TP53; P53\|Homo sapiens (Human) MEEPQSDPSVEPPLSQETFSDLWKLLPENNVLSPLPSQAMDDLMLSPDDIEQWFTEDPGPDEAPRMPEAAPPVAPAPAAPTPAAPAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRVEYLDDRNTFRHSVVVPYEPPEVGSDCTTIHYNYMCNSSCMGGMNRRPILTIITLEDSSGNLLGRNSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNTSSSPQPKKKPLDGEYFTLQIRGRERFEMFRELNEALELKDAQAGKEPGGSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD

※ PTM-Disease Association

Num	PTM	Disease	Cell Type	Type	PTM Site	PMID
1	Acetylation	Breast cancer/tumor/carcinoma		D		24920214
1	[Reference]: Our results provide evidence that melatonin enhances p53 acetylation by modulating the MDM2/MDMX/p300 pathway, disclosing new insights for understanding its anticancer effect.
2	Ubiquitination	Gastric cancer		P		24240108
2	[Reference]: Collectively, our novel findings indicate that AURKA promotes tumor growth and cell survival through regulation of HDM2-induced ubiquitination and inhibition of P53
3	Phosphorylation	Pancreatic cancer/carcinoma/adenocarcinoma		P		23845906
3	[Reference]: Here, we found that cisplatin mainly induced non-apoptotic death of the pancreatic cancer cells (AsPC-1 and Capan-2), which was associated with a significant p53 activation (phosphorylation and accumulation).
4	Phosphorylation	Head and neck squamous cell carcinoma		P		23414419
4	[Reference]: P276-00 treatment suppressed cell proliferation through inhibition of CCND1 expression, reduced phosphorylation of retinoblastoma protein and abrogative transcription of E2F1 gene targets
5	Phosphorylation	Melanoma	A375 cell line	P		22968364
5	[Reference]: Ruthenium complexes containing 2,6-bis(benzimidazolyl)pyridine derivatives induce cancer cell apoptosis by triggering DNA damage-mediated p53 phosphorylation
6	Ubiquitination	Hepatocellular carcinoma/Hepatocarcinoma/Hepatoma		U		16581249
6	[Reference]: Gankyrin regulates the phosphorylation of the retinoblastoma protein (pRb) by CDK4 and enhances the ubiquitylation of p53 by the RING ubiquitin ligase MDM3.
7	Serine Phosphorylation	Breast cancer/tumor/carcinoma	MCF7	A	S15	15958581; 23798621
7	[Reference]: DACH1 phosphorylation at serine residue (S439) inhibited p53 binding and phosphorylation at p53 amino-terminal sites (S15, S20) enhanced DACH1 binding. DACH1 binding to p53 was inhibited by NAD-dependent deacetylation via DACH1 K628. DACH1 repressed p21CIP1 and induced RAD51, an association found in basal breast cancer. DACH1 inhibits breast cancer cellular growth in an NAD and p53-dependent manner through direct protein-protein association.
8	Serine Phosphorylation	Ataxia-telangiectasic cancer		D	S15	9733515
8	[Reference]: Ionizing radiation, but not ultraviolet radiation, rapidly enhanced this p53-directed kinase activity of endogenous ATM. These observations, along with the fact that phosphorylation of p53 on serine-15 in response to ionizing radiation is reduced in ataxia telangiectasia cells, suggest that ATM is a protein kinase that phosphorylates p53 in vivo.
9	Serine Phosphorylation	Brain cancer/tumor	GBM8401 cell line	D	S15	23268709
9	[Reference]: P. indica root aqueous extracts suppress cancer cell proliferation and migration through the phosphorylated-p53 and p21 pathways
10	Serine Phosphorylation	Prostate cancer/carcinoma/adenocarcinoma	cell line	P	S15	23359208
10	[Reference]: AA can activate p53 through increasing the phosphorylation of p53 on Ser15 in LNCaP cells
11	Serine Phosphorylation	Down syndrome		U	S15	20696760
11	[Reference]: Accordingly, brains from embryonic DYRK1A transgenic mice exhibited elevated levels of Dyrk1A, Ser-15 (mouse Ser-18)-phosphorylated p53, and p21(CIP1) as well as impaired neuronal proliferation.
12	Serine Phosphorylation	Colon cancer/carcinoma	cell line	U	S15	25860929
12	[Reference]: FBXW7-mutated colorectal cancer cells exhibit aberrant expression of phosphorylated-p53 at Serine-15.
13	Serine Phosphorylation	Neuroblastoma		U	S15	23824039
13	[Reference]: MPTQ-mediated apoptosis is associated with increased phosphorylation of p53 at Ser15 and Ser20 which correlates with the hyperphosphorylation of Ataxia-Telangiectasia mutated protein (ATM)
14	Serine Phosphorylation	Breast cancer/tumor/carcinoma	MCF7	A	S20	23798621
14	[Reference]: DACH1 phosphorylation at serine residue (S439) inhibited p53 binding and phosphorylation at p53 amino-terminal sites (S15, S20) enhanced DACH1 binding. DACH1 binding to p53 was inhibited by NAD-dependent deacetylation via DACH1 K628. DACH1 repressed p21CIP1 and induced RAD51, an association found in basal breast cancer. DACH1 inhibits breast cancer cellular growth in an NAD and p53-dependent manner through direct protein-protein association.
15	Serine Phosphorylation	Ovarian cancer/carcinoma		U	S20	20009884
15	[Reference]: In p53-positive ovarian carinomas, S392 phosphorylation was associated with advanced tumor stage and high tumor grade. S20 phosphorylation was associated with low tumor grade in p53-positive, and high tumor grade in p53-negative, ovarian carcinomas.
16	Serine Phosphorylation	Neuroblastoma		U	S20	23824039
16	[Reference]: MPTQ-mediated apoptosis is associated with increased phosphorylation of p53 at Ser15 and Ser20 which correlates with the hyperphosphorylation of Ataxia-Telangiectasia mutated protein (ATM)
17	Serine Phosphorylation	B-cell tumor		A	S23	15343266
17	[Reference]: Our finding that S23A/S23A animals are tumor prone suggests that Ser23 phosphorylation is important for the tumor suppressor function of p53.
18	Serine Phosphorylation	T cell lymphoma		N	S37	11042698
18	[Reference]: A serine 37 mutation associated with two missense mutations at highly conserved regions of p53 affect pro-apoptotic genes expression in a T-lymphoblastoid drug resistant cell line.
19	Serine Phosphorylation	Breast cancer/tumor/carcinoma	MCF7	D	S46	17404016
19	[Reference]: Effect of distinct anticancer drugs on the phosphorylation of p53 protein at serine 46 in human MCF-7 breast cancer cells
20	Serine Phosphorylation	Acute lymphoblastic leukaemia		D	S46	23717325; 16377624
20	[Reference]: TP53INP1 Functions as a Tumor Suppressor and Induces Apoptosis through Phosphorylating p53 at Serine-46
21	Serine Phosphorylation	Huntington's disease		U	S46	22011578
21	[Reference]: Mass spectrometry analysis of the post-translational modifications of alpha-enolase from pancreatic ductal adenocarcinoma cells.
22	Arginine Methylation	Lung cancer/carcinoma	H1299 cell line	P	R213	24384472
22	[Reference]: It has been reported that p53 with R213Q mutation is exist in certain tumor cell lines and its methylation on R213 as well
23	Serine Phosphorylation	Lymphoma		D	S312	24173284
23	[Reference]: Our study shows that in addition to protecting against tumours caused by ionising radiation, phosphorylation of p53 on Ser312 also contributes to the suppression of carcinogen-mediated tumourigenesis
24	Lysine Methylation	Glioblastoma		P	K370	22864287
24	[Reference]: We also found that endogenous full-length PHF20 interacted with endogenous p53 in cell lines U87 (glioblastoma) and MCF7 (breast cancer), which both express wild-type p53; PHF20 is an effector protein of p53 double lysine methylation that stabilizes and activates p53.
25	Lysine Methylation	Breast cancer/tumor/carcinoma	MCF7	P	K370	22864287
25	[Reference]: We also found that endogenous full-length PHF20 interacted with endogenous p53 in cell lines U87 (glioblastoma) and MCF7 (breast cancer), which both express wild-type p53; PHF20 is an effector protein of p53 double lysine methylation that stabilizes and activates p53.
26	Lysine Methylation	Lymphoma		D	K372	24189068
26	[Reference]: We also show that reduced PRMT5 expression leads to cyclin D1 transcriptional repression via loss of TP53K372 methylation, which results in decreased BCL3 expression and enhanced recruitment of NF-B p52-HDAC1 repressor complexes to the cyclin D1 promoter.
27	Serine Phosphorylation	Breast cancer/tumor/carcinoma	MCF7	A	S392	21084272
27	[Reference]: lack of phosphorylation at Ser392 may be important in breast cancer pathogenesis and inability to phosphorylate p53 at this site has been related to treatment response
28	Serine Phosphorylation	Vestibular schwannomas		P	S392	16299809
28	[Reference]: Our results suggest that age dependent phosphorylation of p53 protein and deregulation of p53 gene has a role in the development of human vestibular schwannomas.
29	Serine Phosphorylation	Ovarian cancer/carcinoma		U	S392	20009884
29	[Reference]: Expression of p53 protein phosphorylated at serine 20 and serine 392 in malignant and benign ovarian neoplasms: correlation with clinicopathological parameters of tumors.
30	Serine Phosphorylation	Hepatocellular carcinoma/Hepatocarcinoma/Hepatoma		U	S392	21455220
30	[Reference]: Met ensures cell survival through a new path in which c-Abl and p38-MAPK are employed to elicit p53 phosphorylation on Ser(392) and Mdm2 upregulation. We found a clinical correlation between activated Met, phospho-p53, and Mdm2 levels in human tumors, supporting the role of this path in tumorigenesis.

※ Disease Cross-ref Annotation

Database	Annotation
Cancer Gene Census	breast, colorectal, lung, sarcoma, adrenocortical, glioma, Spitzoid tumour, multiple other tumour types breast, sarcoma, adrenocortical carcinoma, glioma, multiple other tumour types Li-Fraumeni syndrome
CTD (Curated) (count: 83) (view all)	MESH:D058186 ; Acute Kidney Injury MESH:D000230 ; Adenocarcinoma MESH:D018262 ; Adenocarcinoma, Clear Cell MESH:C562730 ; Adenocarcinoma Of Esophagus MESH:D000236 ; Adenoma MESH:D000310 ; Adrenal Gland Neoplasms MESH:D018268 ; Adrenocortical Carcinoma MESH:C565972 ; Adrenocortical Carcinoma, Hereditary MESH:D000690 ; Amyotrophic Lateral Sclerosis MESH:D020261 ; Arsenic Poisoning MESH:D001449 ; Balkan Nephropathy MESH:D002545 ; Brain Ischemia MESH:D001943 ; Breast Neoplasms MESH:D002277 ; Carcinoma MESH:D003528 ; Carcinoma, Adenoid Cystic MESH:D002280 ; Carcinoma, Basal Cell MESH:D006528 ; Carcinoma, Hepatocellular MESH:D002292 ; Carcinoma, Renal Cell MESH:D018288 ; Carcinoma, Small Cell MESH:D002294 ; Carcinoma, Squamous Cell MESH:C535575 ; Carcinoma, squamous cell of head and neck MESH:D002295 ; Carcinoma, Transitional Cell MESH:D002312 ; Cardiomyopathy, Hypertrophic MESH:D002340 ; Carotid Artery Diseases MESH:D002471 ; Cell Transformation, Neoplastic MESH:D016543 ; Central Nervous System Neoplasms MESH:D018281 ; Cholangiocarcinoma MESH:C538045 ; Chromosome 17 deletion MESH:D003110 ; Colonic Neoplasms MESH:D015179 ; Colorectal Neoplasms MESH:D003711 ; Demyelinating Diseases MESH:D003921 ; Diabetes Mellitus, Experimental MESH:D004646 ; Emphysema MESH:D004938 ; Esophageal Neoplasms MESH:C562729 ; Esophageal Squamous Cell Carcinoma MESH:D005706 ; Gallbladder Neoplasms MESH:D005910 ; Glioma MESH:D006394 ; Hemangiosarcoma MESH:D006973 ; Hypertension MESH:D007247 ; Infertility, Female MESH:D007248 ; Infertility, Male MESH:D007511 ; Ischemia MESH:D007642 ; Keratosis MESH:C566025 ; Leukemia, Megakaryoblastic, of Down Syndrome MESH:D016864 ; Li-Fraumeni Syndrome MESH:D008109 ; Liver Diseases, Parasitic MESH:D008113 ; Liver Neoplasms MESH:D008114 ; Liver Neoplasms, Experimental MESH:D008175 ; Lung Neoplasms MESH:D015451 ; Leukemia, Lymphocytic, Chronic, B-Cell MESH:D016399 ; Lymphoma, T-Cell MESH:D016410 ; Lymphoma, T-Cell, Cutaneous MESH:D008545 ; Melanoma MESH:C562839 ; Mesothelioma, Malignant MESH:D009062 ; Mouth Neoplasms MESH:D009190 ; Myelodysplastic Syndromes MESH:C538339 ; Nasopharyngeal carcinoma MESH:D009362 ; Neoplasm Metastasis MESH:D002289 ; Carcinoma, Non-Small-Cell Lung MESH:D012516 ; Osteosarcoma MESH:C538090 ; Ovarian epithelial cancer MESH:D010190 ; Pancreatic Neoplasms MESH:D020288 ; Papilloma, Choroid Plexus MESH:D010412 ; Penile Neoplasms MESH:D011123 ; Polyploidy MESH:D054198 ; Precursor Cell Lymphoblastic Leukemia-Lymphoma MESH:D011471 ; Prostatic Neoplasms MESH:D011565 ; Psoriasis MESH:D029424 ; Pulmonary Disease, Chronic Obstructive MESH:D012509 ; Sarcoma MESH:C538639 ; Sarcoma family syndrome of Li and Fraumeni MESH:D012559 ; Schizophrenia MESH:D012751 ; Sezary Syndrome MESH:D012878 ; Skin Neoplasms MESH:D055752 ; Small Cell Lung Carcinoma MESH:D013274 ; Stomach Neoplasms MESH:D013945 ; Thymoma MESH:D013964 ; Thyroid Neoplasms MESH:D001749 ; Urinary Bladder Neoplasms MESH:D014565 ; Urogenital Neoplasms MESH:D014571 ; Urologic Neoplasms MESH:D007724 ; Vulvar Lichen Sclerosus MESH:D009396 ; Wilms Tumor
HGMD (count: 201) (view all)	CP035472; Li-Fraumeni syndrome; Complex rearrangements CD011205; Li-Fraumeni syndrome; Small deletions CD983489; Li-Fraumeni syndrome; Small deletions CD941800; Li-Fraumeni syndrome; Small deletions CD002536; Li-Fraumeni syndrome; Small deletions CD920913; Adrenocortical carcinoma; Small deletions CD951866; Familial brain tumour syndrome; Small deletions CD931244; Li-Fraumeni syndrome; Small deletions CD065798; Breast cancer; Small deletions CD963012; Carcinoma; Small deletions CD031545; Sarcoma; Small deletions CD921041; Sarcoma; Small deletions CD076915; Li-Fraumeni syndrome; Small deletions CD090894; Li-Fraumeni syndrome; Small deletions CD084237; Li-Fraumeni syndrome; Small deletions CD984149; Neuroectodermal tumour; Small deletions CD004355; Li-Fraumeni syndrome; Small deletions CD972478; Li-Fraumeni syndrome; Small deletions CD003107; Li-Fraumeni syndrome; Small deletions CD043957; Li-Fraumeni syndrome; Small deletions CD941799; Li-Fraumeni syndrome; Small deletions CD044990; Li-Fraumeni syndrome; Small deletions CD962734; Li-Fraumeni syndrome; Small deletions CG973544; Li-Fraumeni syndrome; Gross deletions CG942241; Li-Fraumeni syndrome; Gross deletions CX984230; Neuroectodermal tumour; Small indels CX942126; Li-Fraumeni syndrome; Small indels CX952222; Li-Fraumeni syndrome; Small indels CI073781; Li-Fraumeni syndrome; Small insertions CI073782; Li-Fraumeni syndrome; Small insertions CI920954; Li-Fraumeni syndrome; Small insertions CI043961; Li-Fraumeni syndrome; Small insertions CI984665; Li-Fraumeni syndrome; Small insertions CI023564; Choroid plexus tumours; Small insertions CI084335; Li-Fraumeni syndrome; Small insertions CI004819; Medulloblastoma; Small insertions CI045570; Colorectal cancer, increased risk, assoc. with; Small insertions CI084336; Li-Fraumeni syndrome; Small insertions CI920955; Li-Fraumeni syndrome; Small insertions CM074603; Gastric cancer; Missense/nonsense CM052370; Reduced apoptotic ability, association with; Missense/nonsense CM077985; Basal cell carcinoma ?; Missense/nonsense CM961374; Lung cancer, association with; Missense/nonsense CM961375; Breast cancer; Missense/nonsense CM065495; Breast cancer; Missense/nonsense CM045203; Breast cancer; Missense/nonsense CM073388; Li-Fraumeni syndrome; Missense/nonsense CM043949; Li-Fraumeni syndrome; Missense/nonsense CM013441; Carcinoma; Missense/nonsense CM984590; Li-Fraumeni syndrome; Missense/nonsense CM921039; Sarcoma; Missense/nonsense CM065494; Breast cancer; Missense/nonsense CM087281; Choroid plexus carcinoma; Missense/nonsense CM086989; Multiple cancers; Missense/nonsense CM973641; Li-Fraumeni syndrome; Missense/nonsense CM910373; Li-Fraumeni syndrome; Missense/nonsense CM973400; Li-Fraumeni syndrome; Missense/nonsense CM083195; Li-Fraumeni syndrome; Missense/nonsense CM064342; Prostrate cancer; Missense/nonsense CM971503; Li-Fraumeni syndrome; Missense/nonsense CM983475; Li-Fraumeni syndrome; Missense/nonsense CM942116; Glioma; Missense/nonsense CM993216; Li-Fraumeni syndrome; Missense/nonsense CM023462; Li-Fraumeni syndrome; Missense/nonsense CM012662; Li-Fraumeni syndrome; Missense/nonsense CM941326; Astrocytoma; Missense/nonsense CM941327; Adrenocortical carcinoma; Missense/nonsense CM951223; Glioblastoma; Missense/nonsense CM942117; Glioma; Missense/nonsense CM984589; Li-Fraumeni syndrome; Missense/nonsense CM004341; Li-Fraumeni syndrome; Missense/nonsense CM994513; Adrenocortical carcinoma; Missense/nonsense CM983887; Cytosarcoma phyllodes; Missense/nonsense CM942135; Osteosarcoma; Missense/nonsense CM942118; Glioma; Missense/nonsense CM070299; Li-Fraumeni syndrome; Missense/nonsense CM942119; Glioma; Missense/nonsense CM951224; Osteosarcoma; Missense/nonsense CM062017; Adrenocortical carcinoma; Missense/nonsense CM011013; Li-Fraumeni syndrome; Missense/nonsense CM067054; Li-Fraumeni syndrome; Missense/nonsense CM941328; Li-Fraumeni syndrome; Missense/nonsense CM920671; Breast cancer; Missense/nonsense CM056067; Choroid plexus carcinoma, childhood; Missense/nonsense CM942120; Glioma; Missense/nonsense CM920672; Breast cancer; Missense/nonsense CM031755; Multiple cancers; Missense/nonsense CM083194; Li-Fraumeni syndrome; Missense/nonsense CM951225; Li-Fraumeni syndrome; Missense/nonsense CM092575; Glioblastoma & colon cancer; Missense/nonsense CM941329; Adrenocortical carcinoma; Missense/nonsense CM984587; Li-Fraumeni syndrome; Missense/nonsense CM070297; Colorectal cancer; Missense/nonsense CM994748; Multiple cancers; Missense/nonsense CM971504; Osteosarcoma; Missense/nonsense CM004573; Familial adenomatous polyposis; Missense/nonsense CM004906; Choroid plexus carcinoma; Missense/nonsense CM022474; Glioblastoma; Missense/nonsense CM951226; Multiple cancers; Missense/nonsense CM035961; Transcriptional activity, association with; Missense/nonsense CM941330; Adrenocortical carcinoma; Missense/nonsense CM015378; Meningioma; Missense/nonsense CM951227; Li-Fraumeni syndrome; Missense/nonsense CM951228; Rhabdomyosarcoma; Missense/nonsense CM951229; Glioma; Missense/nonsense CM993217; Glioma; Missense/nonsense CM035576; Li-Fraumeni syndrome; Missense/nonsense CM951230; Rhabdomyosarcoma; Missense/nonsense CM941331; Adrenocortical carcinoma; Missense/nonsense CM004907; Li-Fraumeni syndrome; Missense/nonsense CM011014; Li-Fraumeni syndrome; Missense/nonsense CM025271; Li-Fraumeni syndrome; Missense/nonsense CM056070; Choroid plexus carcinoma, childhood; Missense/nonsense CM034930; Leukaemia/lymphoma; Missense/nonsense CM920673; Sarcoma; Missense/nonsense CM942121; Glioma; Missense/nonsense CM910618; Ependymoma; Missense/nonsense CM070298; Breast and colorectal cancer; Missense/nonsense CM056069; Choroid plexus carcinoma, childhood; Missense/nonsense CM920674; Osteosarcoma; Missense/nonsense CM010463; Adenocarcinoma; Missense/nonsense CM900210; Li-Fraumeni syndrome; Missense/nonsense CM900209; Li-Fraumeni syndrome; Missense/nonsense CM010464; Lung cancer; Missense/nonsense CM942294; Multiple cancers; Missense/nonsense CM010465; Thyroid tumour; Missense/nonsense CM900211; Li-Fraumeni syndrome; Missense/nonsense CM920675; Sarcoma; Missense/nonsense CM973401; Colorectal cancer; Missense/nonsense CM951231; Glioma; Missense/nonsense CM900212; Li-Fraumeni syndrome; Missense/nonsense CM951232; Glioblastoma; Missense/nonsense CM941332; Li-Fraumeni syndrome; Missense/nonsense CM900213; Li-Fraumeni syndrome; Missense/nonsense CM971505; Li-Fraumeni syndrome; Missense/nonsense CM921040; Breast cancer; Missense/nonsense CM942136; Osteosarcoma; Missense/nonsense CM920676; Li-Fraumeni syndrome; Missense/nonsense CM942122; Glioma; Missense/nonsense CM920677; Li-Fraumeni syndrome; Missense/nonsense CM010472; Carcinoma; Missense/nonsense CM004342; Multiple cancers; Missense/nonsense CM010473; Carcinoma; Missense/nonsense CM010471; Leukaemia/lymphoma; Missense/nonsense CM951233; Li-Fraumeni syndrome; Missense/nonsense CM951234; Li-Fraumeni syndrome; Missense/nonsense CM076568; Li-Fraumeni-like syndrome; Missense/nonsense CM065496; Breast cancer, increased risk; Missense/nonsense CM961376; Breast cancer; Missense/nonsense CM052927; Li-Fraumeni syndrome; Missense/nonsense CM011015; Li-Fraumeni syndrome; Missense/nonsense CM993218; Glioma; Missense/nonsense CM076566; Breast cancer; Missense/nonsense CM056068; Choroid plexus carcinoma, childhood; Missense/nonsense CM004343; Osteosarcoma; Missense/nonsense CM056413; Li-Fraumeni syndrome; Missense/nonsense CM920678; Osteosarcoma; Missense/nonsense CM004344; Neuroblastoma; Missense/nonsense CM021154; Astrocytoma; Missense/nonsense CM041458; Gastric cancer; Missense/nonsense CM995136; Multiple cancers; Missense/nonsense CM083790; Choroid plexus carcinoma, childhood; Missense/nonsense CM920679; Adrenocortical carcinoma; Missense/nonsense CM076567; Li-Fraumeni-like syndrome; Missense/nonsense CM044948; Li-Fraumeni syndrome; Missense/nonsense CM993905; Li-Fraumeni syndrome; Missense/nonsense CM065493; Li-Fraumeni syndrome; Missense/nonsense CM994791; Li-Fraumeni syndrome; Missense/nonsense CM910627; Astrocytoma; Missense/nonsense CM031387; Sarcoma; Missense/nonsense CM942123; Glioma; Missense/nonsense CM951235; Rhabdomyosarcoma; Missense/nonsense CM971506; Li-Fraumeni syndrome; Missense/nonsense CM055562; Li-Fraumeni syndrome; Missense/nonsense CM920680; Li-Fraumeni syndrome; Missense/nonsense CM044725; Multiple cancers; Missense/nonsense CM012663; Adrenocortical carcinoma; Missense/nonsense CM981929; Li-Fraumeni syndrome; Missense/nonsense CM984588; Li-Fraumeni syndrome; Missense/nonsense CM004908; Li-Fraumeni-like syndrome; Missense/nonsense CM961377; Li-Fraumeni syndrome; Missense/nonsense CM073387; Li-Fraumeni syndrome; Missense/nonsense CM035962; Transcriptional activity, association with; Missense/nonsense CM031388; Sarcoma; Missense/nonsense CS002469; Li-Fraumeni syndrome; Splicing CS011572; Li-Fraumeni syndrome; Splicing CS971912; Li-Fraumeni syndrome; Splicing CS971913; Li-Fraumeni syndrome; Splicing CS951538; Li-Fraumeni syndrome; Splicing CS004351; Li-Fraumeni syndrome; Splicing CS011573; Li-Fraumeni syndrome; Splicing CS941545; Breast cancer; Splicing CS011574; Li-Fraumeni syndrome; Splicing CS083991; Li-Fraumeni syndrome; Splicing CS034998; Li-Fraumeni syndrome; Splicing CS971914; Li-Fraumeni syndrome; Splicing CS011061; Li-Fraumeni syndrome; Splicing CS004882; Breast cancer; Splicing CS071266; Carcinoma of Ampulla of Vater; Splicing CS033842; Sarcoma; Splicing CS002470; Li-Fraumeni syndrome; Splicing
GWASdb (count: 8) (view all)	rs78378222; Skin cancer (cutaneous basal cell carcinoma); pigmented basal cell carcinoma rs78378222; Basal cell carcinoma; basal cell carcinoma rs12951053; Hematology traits; myocardial infarction\|nephrotic syndrome\|hypersensitivity reaction type II disease\|hematopoietic system disease rs1625895; Sex hormone-binding globulin levels; breast cancer rs1042522; Drug response to Fluorouracil; Null rs1042522; Drug response to Cisplatin; Null rs1042522; Drug response to Cyclophosphamide; Null rs8078476; HDL cholesterol; cholesterol ester storage disease\|cholesterol embolism\|coronary artery disease

※ PTM Sites

PTM	Modification Sites
Phosphorylation (count: 35) (view all)	106 SQKTYQGSYGFRLGF dbPAF 126 AKSVTCTYSPALNKM dbPAF 149 PVQLWVDSTPPPGTR dbPAF 15 PSVEPPLSQETFSDL dbPAF 150 VQLWVDSTPPPGTRV dbPAF 155 DSTPPPGTRVRAMAI dbPAF 18 EPPLSQETFSDLWKL dbPAF 183 CPHHERCSDSDGLAP dbPAF 20 PLSQETFSDLWKLLP dbPAF 211 EYLDDRNTFRHSVVV dbPAF 215 DRNTFRHSVVVPYEP dbPAF 220 RHSVVVPYEPPEVGS dbPAF 269 GNLLGRNSFEVRVCA dbPAF 284 CPGRDRRTEEENLRK dbPAF 312 KRALPNNTSSSPQPK dbPAF 313 RALPNNTSSSPQPKK dbPAF 314 ALPNNTSSSPQPKKK dbPAF 315 LPNNTSSSPQPKKKP dbPAF 327 KKPLDGEYFTLQIRG dbPAF 33 LPENNVLSPLPSQAM dbPAF 362 AGKEPGGSRAHSSHL dbPAF 366 PGGSRAHSSHLKSKK dbPAF 37 NVLSPLPSQAMDDLM dbPAF 371 AHSSHLKSKKGQSTS dbPAF 376 LKSKKGQSTSRHKKL dbPAF 377 KSKKGQSTSRHKKLM dbPAF 378 SKKGQSTSRHKKLMF dbPAF 387 HKKLMFKTEGPDSD* dbPAF 392 FKTEGPDSD**** dbPAF 46 AMDDLMLSPDDIEQW dbPAF 55 DDIEQWFTEDPGPDE dbPAF 6 MEEPQSDPSVEPP dbPAF 81 APAPAAPTPAAPAPA dbPAF 9 EEPQSDPSVEPPLSQ dbPAF 99 PLSSSVPSQKTYQGS dbPAF
Acetylation (count: 14) (view all)	120 FLHSGTAKSVTCTYS PLMD 164 VRAMAIYKQSQHMTE PLMD 292 EEENLRKKGEPHHEL PLMD 305 ELPPGSTKRALPNNT PLMD 319 TSSSPQPKKKPLDGE PLMD 320 SSSPQPKKKPLDGEY PLMD 321 SSPQPKKKPLDGEYF PLMD 357 LKDAQAGKEPGGSRA PLMD 370 RAHSSHLKSKKGQST PLMD 372 HSSHLKSKKGQSTSR PLMD 373 SSHLKSKKGQSTSRH PLMD 381 GQSTSRHKKLMFKTE PLMD 382 QSTSRHKKLMFKTEG PLMD 386 RHKKLMFKTEGPDSD PLMD
Ubiquitination (count: 14) (view all)	101 SSSVPSQKTYQGSYG PLMD 120 FLHSGTAKSVTCTYS PLMD 132 TYSPALNKMFCQLAK PLMD 139 KMFCQLAKTCPVQLW PLMD 164 VRAMAIYKQSQHMTE PLMD 291 TEEENLRKKGEPHHE PLMD 292 EEENLRKKGEPHHEL PLMD 305 ELPPGSTKRALPNNT PLMD 320 SSSPQPKKKPLDGEY PLMD 321 SSPQPKKKPLDGEYF PLMD 351 LNEALELKDAQAGKE PLMD 357 LKDAQAGKEPGGSRA PLMD 370 RAHSSHLKSKKGQST PLMD 386 RHKKLMFKTEGPDSD PLMD
Sumoylation (count: 1)	386 RHKKLMFKTEGPDSD PLMD
Butyrylation (count: 5)	319 TSSSPQPKKKPLDGE PLMD 320 SSSPQPKKKPLDGEY PLMD 372 HSSHLKSKKGQSTSR PLMD 373 SSHLKSKKGQSTSRH PLMD 382 QSTSRHKKLMFKTEG PLMD
Methylation (count: 5)	370 RAHSSHLKSKKGQST PLMD 372 HSSHLKSKKGQSTSR PLMD 373 SSHLKSKKGQSTSRH PLMD 382 QSTSRHKKLMFKTEG PLMD 386 RHKKLMFKTEGPDSD PLMD
Propionylation (count: 3)	292 EEENLRKKGEPHHEL PLMD 319 TSSSPQPKKKPLDGE PLMD 320 SSSPQPKKKPLDGEY PLMD
Neddylation (count: 5)	320 SSSPQPKKKPLDGEY PLMD 321 SSPQPKKKPLDGEYF PLMD 370 RAHSSHLKSKKGQST PLMD 372 HSSHLKSKKGQSTSR PLMD 373 SSHLKSKKGQSTSRH PLMD

※ Protein-Protein Interaction

Network

Interaction

Source

A8MT69	P04637	HPRD
A9UF04	P04637	MINT
B1AJR8	P04637	BioGRID
B7Z4V2	P04637	MINT
C9JP52	P04637	BioGRID
E7ESA6	P04637	HPRD; IntAct; MINT
E7EX81	P04637	HPRD; MINT
E9PAT7	P04637	HPRD
E9PFC7	P04637	HPRD
E9PG89	P04637	HPRD
E9PHZ3	P04637	HPRD
E9PMS4	P04637	BioGRID
F5GXF0	P04637	HPRD; MINT
F5HB16	P04637	BioGRID
F8WEU1	P04637	MINT
G3V1P6	P04637	HPRD
G3V1V9	P04637	IntAct
H0Y7U1	P04637	BioGRID
H0YBT0	P04637	IntAct
H0YG33	P04637	HPRD
H3BSF1	P04637	MINT
H7C2I1	P04637	HPRD
O00231	P04637	HPRD; IntAct; MINT
O00255	P04637	IntAct
O14503	P04637	MINT
O14576	P04637	MINT
O14641	P04637	HPRD; IntAct; MINT
O14757	P04637	HPRD; MINT
O14920	P04637	DIP; MINT
O14965	P04637	HPRD
O14980	P04637	DIP; MINT
O15111	P04637	HPRD
O15126	P04637	HPRD; IntAct; MINT
O15151	P04637	HPRD; DIP; IntAct; MINT
O15169	P04637	IntAct
O15297	P04637	HPRD
O15350	P04637	HPRD
O15379	P04637	HPRD; IntAct
O43257	P04637	HPRD
O43261	P04637	HPRD; IntAct; MINT
O43474	P04637	HPRD
O43524	P04637	IntAct
O43715	P04637	HPRD
O60285	P04637	IntAct
O60551	P04637	HPRD; MINT
O60729	P04637	HPRD
O60936	P04637	DIP
O75150	P04637	IntAct
O75528	P04637	HPRD
O75569	P04637	HPRD
O75925	P04637	HPRD; IntAct
O75928	P04637	IntAct
O95376	P04637	HPRD; IntAct; MINT
O95863	P04637	MINT
O95967	P04637	HPRD
O95997	P04637	HPRD
O96017	P04637	MINT;HPRD
P00374	P04637	HPRD
P00480	P04637	BioGRID
P00491	P04637	HPRD; IntAct; MINT
P00519	P04637	HPRD
P02749	P04637	IntAct
P03120	P04637	MINT
P03372	P04637	HPRD
P04019	P04637	MINT
P04150	P04637	HPRD
P04183	P04637	HPRD; IntAct; MINT
P04271	P04637	HPRD
P04637	P04637	HPRD; DIP; IntAct; MINT
P04637	P04792	HPRD; IntAct; MINT
P04637	P05109	HPRD; IntAct; MINT
P04637	P05112	BioGRID
P04637	P05387	BioGRID
P04637	P05549	HPRD
P04637	P06400	IntAct
P04637	P06493	HPRD; DIP
P04637	P06748	HPRD; IntAct; MINT;IntAct
P04637	P07384	HPRD
P04637	P07900	HPRD; DIP
P04637	P08047	HPRD; MINT
P04637	P08238	HPRD
P04637	P09429	HPRD; DIP; IntAct
P04637	P09529	BioGRID
P04637	P09874	HPRD; DIP; IntAct; MINT
P04637	P09884	HPRD
P04637	P0CG47	HPRD; IntAct
P04637	P0CG48	MINT
P04637	P10275	MINT
P04637	P10415	HPRD; DIP; IntAct; MINT
P04637	P10828	HPRD; DIP
P04637	P11021	MINT
P04637	P11274	HPRD; IntAct
P04637	P11387	HPRD
P04637	P11388	HPRD
P04637	P12004	BioGRID
P04637	P12429	HPRD; IntAct; MINT
P04637	P12956	HPRD; IntAct
P04637	P13497	IntAct
P04637	P13639	HPRD
P04637	P13693	MINT
P04637	P14174	HPRD
P04637	P15559	HPRD; DIP
P04637	P17028	HPRD; IntAct; MINT
P04637	P17252	HPRD
P04637	P17676	IntAct
P04637	P17844	HPRD; IntAct;IntAct
P04637	P18146	HPRD
P04637	P18283	IntAct
P04637	P18754	MINT
P04637	P18847	HPRD; IntAct
P04637	P18887	IntAct
P04637	P19447	HPRD
P04637	P19525	HPRD
P04637	P19544	HPRD
P04637	P20023	HPRD
P04637	P20042	HPRD; IntAct; MINT
P04637	P20073	MINT
P04637	P20226	HPRD; IntAct
P04637	P20248	HPRD
P04637	P20338	HPRD; IntAct; MINT
P04637	P21673	HPRD; IntAct; MINT
P04637	P23511	IntAct;HPRD
P04637	P24522	MINT
P04637	P24941	HPRD
P04637	P25208	HPRD; IntAct
P04637	P25963	HPRD
P04637	P26447	HPRD; MINT
P04637	P26583	HPRD
P04637	P27361	HPRD
P04637	P27694	HPRD; DIP; IntAct
P04637	P27695	HPRD
P04637	P28360	HPRD
P04637	P28482	HPRD
P04637	P29034	HPRD
P04637	P29320	HPRD
P04637	P29590	HPRD; IntAct; MINT;IntAct
P04637	P29965	HPRD
P04637	P30153	MINT
P04637	P30419	HPRD; MINT
P04637	P31350	HPRD; DIP
P04637	P31947	IntAct
P04637	P32745	HPRD
P04637	P32780	HPRD; MINT
P04637	P34931	MINT
P04637	P35232	HPRD; IntAct; MINT
P04637	P35354	HPRD
P04637	P36405	HPRD; IntAct; MINT
P04637	P36873	HPRD;IntAct
P04637	P36956	IntAct
P04637	P38398	DIP; MINT
P04637	P38646	HPRD; MINT
P04637	P38936	MINT
P04637	P41218	HPRD; MINT
P04637	P41235	HPRD
P04637	P42345	MINT
P04637	P42680	HPRD
P04637	P42694	MINT
P04637	P42773	HPRD; IntAct; MINT
P04637	P42858	HPRD; IntAct
P04637	P43356	IntAct
P04637	P45983	HPRD; MINT
P04637	P45984	HPRD
P04637	P46821	MINT
P04637	P48643	HPRD; IntAct; MINT
P04637	P48729	HPRD
P04637	P48730	HPRD; MINT
P04637	P49459	HPRD; DIP
P04637	P49642	HPRD
P04637	P49841	MINT;HPRD
P04637	P49848	DIP
P04637	P49888	HPRD; IntAct; MINT
P04637	P50453	HPRD; IntAct; MINT
P04637	P50748	BioGRID
P04637	P50750	HPRD
P04637	P51532	IntAct
P04637	P51587	HPRD; DIP
P04637	P51784	IntAct
P04637	P51813	IntAct; MINT
P04637	P51946	HPRD
P04637	P51948	HPRD
P04637	P51959	HPRD
P04637	P52292	HPRD
P04637	P53350	HPRD; MINT
P04637	P53779	HPRD
P04637	P54132	HPRD
P04637	P55060	IntAct
P04637	P55199	HPRD
P04637	P55209	HPRD
P04637	P55774	HPRD; IntAct; MINT
P04637	P60484	HPRD
P04637	P60568	BioGRID
P04637	P60953	HPRD; IntAct; MINT
P04637	P61086	HPRD
P04637	P61201	HPRD
P04637	P61224	MINT
P04637	P61289	MINT;HPRD
P04637	P61964	IntAct
P04637	P61978	MINT
P04637	P61981	HPRD
P04637	P62081	IntAct
P04637	P62136	MINT;HPRD
P04637	P62328	IntAct
P04637	P62988	DIP
P04637	P63104	HPRD; MINT
P04637	P63151	MINT
P04637	P63162	HPRD; IntAct
P04637	P63165	HPRD; DIP
P04637	P63279	HPRD; DIP; IntAct; MINT
P04637	P67775	HPRD
P04637	P67809	HPRD
P04637	P68133	HPRD
P04637	P68400	HPRD
P04637	P78527	HPRD
P04637	P84022	HPRD
P04637	P84090	HPRD; IntAct; MINT
P04637	Q00005	HPRD
P04637	Q00535	HPRD
P04637	Q00987	HPRD; DIP; IntAct; MINT
P04637	Q01094	HPRD
P04637	Q01484	IntAct
P04637	Q02447	HPRD
P04637	Q02880	HPRD
P04637	Q03013	HPRD; IntAct; MINT
P04637	Q03164	IntAct
P04637	Q03468	HPRD
P04637	Q03701	HPRD; MINT
P04637	Q05086	HPRD; IntAct; MINT
P04637	Q06187	HPRD
P04637	Q06609	IntAct;HPRD
P04637	Q06945	DIP
P04637	Q07817	HPRD; MINT;IntAct
P04637	Q09472	HPRD; DIP; IntAct; MINT
P04637	Q12772	IntAct
P04637	Q12824	HPRD
P04637	Q12873	MINT
P04637	Q12888	HPRD; DIP; IntAct
P04637	Q13043	HPRD
P04637	Q13098	HPRD
P04637	Q13155	DIP
P04637	Q13190	HPRD; IntAct; MINT
P04637	Q13227	HPRD
P04637	Q13263	IntAct
P04637	Q13315	HPRD; MINT
P04637	Q13330	HPRD
P04637	Q13362	MINT
P04637	Q13526	HPRD; IntAct; MINT
P04637	Q13535	HPRD; IntAct
P04637	Q13547	HPRD; IntAct; MINT
P04637	Q13625	DIP; IntAct; MINT;HPRD
P04637	Q13972	MINT
P04637	Q14061	HPRD; IntAct; MINT
P04637	Q14151	MINT
P04637	Q14186	HPRD
P04637	Q14191	HPRD; IntAct
P04637	Q14676	HPRD
P04637	Q14695	IntAct; MINT
P04637	Q14974	HPRD
P04637	Q14999	IntAct
P04637	Q15013	IntAct; MINT
P04637	Q15102	HPRD; IntAct; MINT
P04637	Q15181	HPRD; IntAct
P04637	Q15291	IntAct
P04637	Q15392	HPRD
P04637	Q15424	MINT
P04637	Q15486	HPRD; IntAct; MINT
P04637	Q15572	HPRD
P04637	Q15573	HPRD
P04637	Q15596	IntAct
P04637	Q15648	HPRD; DIP; MINT
P04637	Q15672	IntAct
P04637	Q15759	IntAct
P04637	Q15796	HPRD; IntAct
P04637	Q15831	HPRD; IntAct
P04637	Q15843	HPRD
P04637	Q16363	HPRD; IntAct
P04637	Q16539	MINT
P04637	Q16594	HPRD; DIP
P04637	Q16611	HPRD
P04637	Q16637	HPRD; MINT
P04637	Q16665	HPRD
P04637	Q16666	DIP;HPRD
P04637	Q2KN33	MINT
P04637	Q4LE28	HPRD; DIP; MINT
P04637	Q53GS9	IntAct
P04637	Q53T94	HPRD
P04637	Q5JVS0	HPRD
P04637	Q5SRQ6	HPRD
P04637	Q5VTR2	IntAct
P04637	Q66K89	HPRD
P04637	Q6LET9	MINT
P04637	Q6NUQ0	MINT
P04637	Q6UW56	MINT
P04637	Q6ZSW6	MINT
P04637	Q7L1I2	BioGRID
P04637	Q7L5N1	HPRD
P04637	Q7LG56	HPRD; DIP
P04637	Q7Z2E3	IntAct
P04637	Q7Z566	MINT
P04637	Q7Z6Z7	IntAct;HPRD
P04637	Q86TM6	HPRD; MINT
P04637	Q86WX3	IntAct
P04637	Q86XK2	HPRD; IntAct
P04637	Q86Z02	HPRD; IntAct
P04637	Q8IW41	HPRD; IntAct
P04637	Q8IWT3	HPRD; IntAct
P04637	Q8IZD2	IntAct
P04637	Q8N114	HPRD
P04637	Q8N2W9	HPRD; IntAct; MINT
P04637	Q8N488	MINT
P04637	Q8N726	DIP; IntAct
P04637	Q8N9B5	IntAct
P04637	Q8N9N5	MINT;HPRD
P04637	Q8NA92	HPRD; IntAct; MINT
P04637	Q8NHY2	HPRD; IntAct; MINT
P04637	Q8TAF3	IntAct
P04637	Q8TAQ5	MINT
P04637	Q8TBK6	IntAct; MINT;HPRD
P04637	Q8TDN4	HPRD; IntAct
P04637	Q8TDT2	BioGRID
P04637	Q8TDY2	IntAct
P04637	Q8WTS6	HPRD; DIP; IntAct
P04637	Q8WUF5	HPRD; DIP; MINT
P04637	Q8WWV6	IntAct
P04637	Q8WYH8	HPRD
P04637	Q92754	HPRD
P04637	Q92769	HPRD
P04637	Q92793	IntAct
P04637	Q92831	HPRD; IntAct
P04637	Q92841	IntAct
P04637	Q92890	MINT
P04637	Q92905	HPRD
P04637	Q92922	IntAct
P04637	Q92993	IntAct;HPRD
P04637	Q92994	HPRD
P04637	Q93009	HPRD; DIP; IntAct; MINT
P04637	Q96A56	HPRD
P04637	Q96EB6	HPRD; IntAct
P04637	Q96G74	IntAct
P04637	Q96GM5	HPRD
P04637	Q96GM8	MINT
P04637	Q96KB5	HPRD; IntAct
P04637	Q96KQ4	MINT
P04637	Q96M61	HPRD; IntAct; MINT
P04637	Q96PM5	HPRD; DIP; IntAct; MINT
P04637	Q96PM9	IntAct
P04637	Q96PU4	IntAct
P04637	Q96S44	HPRD
P04637	Q96SB4	MINT
P04637	Q96ST3	HPRD; IntAct
P04637	Q99547	HPRD; IntAct; MINT
P04637	Q99608	HPRD
P04637	Q99612	HPRD
P04637	Q99627	HPRD
P04637	Q99728	HPRD; IntAct
P04637	Q99816	HPRD
P04637	Q99856	HPRD
P04637	Q99966	IntAct
P04637	Q99973	HPRD
P04637	Q99986	HPRD; IntAct
P04637	Q9BQD7	HPRD; IntAct
P04637	Q9BT78	HPRD
P04637	Q9BTK6	MINT
P04637	Q9BTV7	HPRD
P04637	Q9BUJ2	IntAct;HPRD; MINT
P04637	Q9BV47	IntAct
P04637	Q9BVP2	HPRD; IntAct
P04637	Q9BWC9	HPRD; IntAct; MINT
P04637	Q9BX70	HPRD; IntAct; MINT
P04637	Q9C0J8	HPRD; IntAct
P04637	Q9GZV1	HPRD
P04637	Q9H0Q3	IntAct; MINT
P04637	Q9H2X6	HPRD; IntAct; MINT
P04637	Q9H3D4	HPRD; IntAct
P04637	Q9H3E2	BioGRID
P04637	Q9H4B4	HPRD
P04637	Q9H7Z6	IntAct; MINT
P04637	Q9H9J4	MINT
P04637	Q9HBD4	HPRD
P04637	Q9HBJ7	MINT
P04637	Q9HBM6	HPRD
P04637	Q9NPI1	DIP; IntAct
P04637	Q9NRG4	HPRD; DIP
P04637	Q9NS56	HPRD; MINT
P04637	Q9NTD8	DIP
P04637	Q9NVC6	HPRD
P04637	Q9NVN8	IntAct
P04637	Q9NZB8	MINT
P04637	Q9NZC7	HPRD; MINT
P04637	Q9UBE0	MINT
P04637	Q9UBF1	IntAct
P04637	Q9UBW8	HPRD
P04637	Q9UER7	HPRD; DIP; IntAct
P04637	Q9UHC7	MINT
P04637	Q9UK53	HPRD
P04637	Q9UKY1	HPRD; MINT
P04637	Q9UM63	HPRD
P04637	Q9UN74	HPRD; IntAct; MINT
P04637	Q9UNH5	HPRD
P04637	Q9UNL4	MINT;HPRD
P04637	Q9UNS2	HPRD
P04637	Q9UQR1	HPRD
P04637	Q9Y276	MINT
P04637	Q9Y297	DIP
P04637	Q9Y2A0	IntAct
P04637	Q9Y3T9	IntAct
P04637	Q9Y675	MINT
P04637	RTD	DIP

PTMD Annotation Information

※ Protein Information

Functional Description

Fasta Sequence

※ PTM-Disease Association

※ Disease Cross-ref Annotation

※ PTM Sites

※ Protein-Protein Interaction